David Wonderling, MSc; Laura Sawyer, MSc; Elisabetta Fenu, MSc; Kate Lovibond, MSc; Philippe Laramée, DC, MSc
The National Clinical Guideline Centre (NCGC) develops evidence-based clinical guidelines on behalf of the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom. The U.K. Department of Health has commissioned NICE to make recommendations on the basis of both clinical effectiveness and cost-effectiveness. This article describes how cost-effectiveness is evaluated and accounted for in NCGC guidelines. Six recent case studies are presented, in which consideration of cost-effectiveness has informed recommendations in various ways for clinical guidelines on alcohol use disorders, chronic obstructive pulmonary disease, glaucoma, lower urinary tract symptoms, non–ST-segment elevation myocardial infarction and unstable angina, and venous thromboembolism prophylaxis. Some of the challenges faced in trying to account for cost-effectiveness in clinical guidelines are outlined, as well as some of the difficulties in adapting cost-effectiveness guidelines for other settings.
ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.
Appendix Table 1.
Appendix Table 2.
Appendix Table 3.
Wonderling D, Sawyer L, Fenu E, et al. National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence. Ann Intern Med. 2011;154:758–765. doi: https://doi.org/10.7326/0003-4819-154-11-201106070-00008
Download citation file:
Published: Ann Intern Med. 2011;154(11):758-765.
Guidelines, High Value Care.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use